Table 2: Profiles and clinical outcomes of patients who completed the regimen 

Clinical Background						Immunological Response		Antitumor Response
Dose	Age	Gender	Origin	Status	HLA class I	Tetramer increase	ELISPOT increase	RECIST	CEA	CA19-9
0.3 mg	63	Woman	Pancreas	Inoperable	+	35	-17	SD	Decreased	Decreased
0.3 mg	69	Woman	Pancreas	Inoperable	+	5	-31	SD	WNL	Increased
0.3 mg	53	Woman	Pancreas	Post-op	-	7	6	PD	Increased	Increased
0.3 mg	68	Man	Pancreas	Post-op	+	+	17	PD	Increased	Increased
0.3 mg	78	Man	Man	Post-op	+	-4	2	PD	Increased	Increased
1.0 mg	61	Man	Pancreas	Inoperable	+	21	-1	SD	Increased	Increased
1.0 mg	84	Woman	Colon	Post-op	+	28	14	SD	Increased	Increased
1.0 mg	69	Man	Stomach	Post-op	+	7	26	SD	Increased	Increased
1.0 mg	59	Man	Colon	Post-op	+	29	16	PD	Increased	Increased
1.0 mg	62	Man	Colon	Post-op	+	15	2	PD	Increased	WNL
3.0 mg	41	Woman	Pancreas	Post-op	+	12	158	SD	WNL	Stable
3.0 mg	66	Man	Pancreas	Inoperable	+	12	19	SD	Decreased	Increased
3.0 mg	64	Man	Pancreas	Post-op	+	2	-16	SD	WNL	Decreased
3.0 mg	50	Man	Pancreas	Post-op	+	12	21	PD	WNL	Increased
3.0 mg	64	Woman	Pancreas	Inoperable	+	0	10	PD	Increased	Increased

Post-op: Post-Operative, SD: Stable Disease, PD: Progressive Disease, WNL: Within the Normal Limit